Real-world experience of angiotensin receptor-neprilysin inhibitors in patients with heart failure and dialysis.

Front Cardiovasc Med · 2024 · PMC11298400 · PMID 39105079

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Importantly, while the advantageous effects of ARNI may be less pronounced in patients with both HFrEF and ESRD undergoing dialysis, the ARNI group showed a trend towards lower risks of hypotension and hyperkalemia.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.